BioAegis Therapeutics, Inc.转发了
Exciting Clinical Trial Update! - Over 23 sites in 7 countries are live -- and increasing daily. - First patients have been enrolled in both Europe and the US. BioAegis is making big strides with our groundbreaking?600-person global phase 2 clinical trial?of recombinant human plasma gelsolin (rhu-pGSN) for moderate to severe?Acute Respiratory Distress Syndrome (#ARDS). ARDS is a life threatening lung condition with a 40% mortality rate, yet there are no approved pharmacological treatments for this deadly condition. The lack of effective therapies to treat ARDS and its associated high mortality driven by excess #inflammation underscores the urgent need for an innovative therapy in this field. #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator of inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. #BioAegis, #clinicaltrials, #lungs, #lungdamage??#respiratoryfailure #savinglives #biotechinvesting #biotech ARDS Alliance Valerie Ceva Susan Levinson Steven Cordovano